

Supplementary Table 3. Common therapies for platinum-resistant epithelial ovarian cancer.

Single-Agent Chemotherapy^a

- A. Liposomal Doxorubicin²⁰
- B. Topotecan²¹
- C. Paclitaxel²²
- D. Gemzar²³
- E. Bevacizumab²⁴
- F. Nabpaclitaxel²⁵
- G. Oral Etoposide²⁶
- H. Pemetrexed²⁷
- I. Docetaxel²⁸

Combination chemotherapy with anti-angiogenesis^a

- A. Liposomal doxorubicin/bevacizumab every 28 days²⁹
- B. Paclitaxel/bevacizumab every 28 days²⁹
- C. Topotecan/bevacizumab every 28 days²⁹
- D. Nabpaclitaxel/bevacizumab³⁰

Endocrine therapy^a

- A. Tamoxifen³¹
- B. Letrozole^{b 32}
- C. Fulvestrant every 28 days^{b 33}

PARPi

- A. Olaparib^{c 34}
- B. Rucaparib^{d 35}

^acontinued until disease progression or unacceptable toxicity

^bestrogen-receptor positive patients only

^cgermline BRCA1 or BRCA2 deficient patients only

^dgermline BRCA1 or BRCA2 mutations patients or somatic loss of heterozygosity (high)